Literature DB >> 21730052

Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response.

Hongliang Fang1, Yanfeng Wu, Xiaohui Huang, Wenying Wang, Bing Ang, Xuetao Cao, Tao Wan.   

Abstract

Toll-like receptors (TLRs) play important roles in initiation of innate and adaptive immune responses. Emerging evidence suggests that TLR agonists can serve as potential adjuvant for vaccination. Heat shock proteins (HSPs), functionally serving as TLR4 agonists, have been proposed to act as Th1 adjuvant. We have identified a novel Hsp70 family member, termed Hsp70-like protein 1 (Hsp70L1), shown that Hsp70L1 is a potent T helper cell (Th1) polarizing adjuvant that contributes to antitumor immune responses. However, the underlying mechanism for how Hsp70L1 exerts its Th1 adjuvant activity remains to be elucidated. In this study, we found that Hsp70L1 binds directly to TLR4 on the surface of DCs, activates MAPK and NF-κB pathways, up-regulates I-a(b), CD40, CD80, and CD86 expression and promotes production of TNF-α, IL-1β, and IL-12p70. Hsp70L1 failed to induce such phenotypic maturation and cytokine production in TLR4-deficient DCs, indicating a role for TLR4 in mediating Hsp70L1-induced DC activation. Furthermore, more efficient induction of carcinoembryonic antigen (CEA)-specific Th1 immune response was observed in mice immunized by wild-type DCs pulsed with Hsp70L1-CEA(576-669) fusion protein as compared with TLR4-deficient DCs pulsed with same fusion protein. In addition, TLR4 antagonist impaired induction of CEA-specific human Th1 immune response in a co-culture system of peripheral blood lymphocytes (PBLs) from HLA-A2.1(+) healthy donors and autologous DCs pulsed with Hsp70L1-CEA(576-669) in vitro. Taken together, these results demonstrate that TLR4 is a key receptor mediating the interaction of Hsp70L1 with DCs and subsequently enhancing the induction of Th1 immune response by Hsp70L1/antigen fusion protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21730052      PMCID: PMC3162398          DOI: 10.1074/jbc.M111.266528

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

2.  An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Authors:  Christopher Wood; Pramod Srivastava; Ronald Bukowski; Louis Lacombe; Andrei I Gorelov; Sergei Gorelov; Peter Mulders; Henryk Zielinski; Axel Hoos; Florentina Teofilovici; Leah Isakov; Robert Flanigan; Robert Figlin; Renu Gupta; Bernard Escudier
Journal:  Lancet       Date:  2008-07-03       Impact factor: 79.321

Review 3.  Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.

Authors:  Amit Lahiri; Priyanka Das; Dipshikha Chakravortty
Journal:  Vaccine       Date:  2008-10-07       Impact factor: 3.641

4.  Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis.

Authors:  Mieke F Roelofs; Wilbert C Boelens; Leo A B Joosten; Shahla Abdollahi-Roodsaz; Jeroen Geurts; Liza U Wunderink; B Willem Schreurs; Wim B van den Berg; Timothy R D J Radstake
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

5.  Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors.

Authors:  Masashi Murata
Journal:  Cancer Sci       Date:  2008-04-29       Impact factor: 6.716

6.  Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Authors:  Alessandro Testori; Jon Richards; Eric Whitman; G Bruce Mann; Jose Lutzky; Luis Camacho; Giorgio Parmiani; Giulio Tosti; John M Kirkwood; Axel Hoos; Lianng Yuh; Renu Gupta; Pramod K Srivastava
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

7.  TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta.

Authors:  Jonathan C Kagan; Tian Su; Tiffany Horng; Amy Chow; Shizuo Akira; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2008-02-24       Impact factor: 25.606

8.  The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Authors:  Verónica Mata-Haro; Caglar Cekic; Michael Martin; Paula M Chilton; Carolyn R Casella; Thomas C Mitchell
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

9.  Complement C1q chemoattracts human dendritic cells and enhances migration of mature dendritic cells to CCL19 via activation of AKT and MAPK pathways.

Authors:  Shuxun Liu; Jiang Wu; Ting Zhang; Baohua Qian; Pingping Wu; Li Li; Yizhi Yu; Xuetao Cao
Journal:  Mol Immunol       Date:  2008-10-05       Impact factor: 4.407

10.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems.

Authors:  Anna M Lundberg; Stefan K Drexler; Claudia Monaco; Lynn M Williams; Sandra M Sacre; Marc Feldmann; Brian M Foxwell
Journal:  Blood       Date:  2007-07-27       Impact factor: 22.113

View more
  37 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

Review 2.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

3.  MicroRNAs in the regulation of immune response against infections.

Authors:  Yue Zhang; Ying-ke Li
Journal:  J Zhejiang Univ Sci B       Date:  2013-01       Impact factor: 3.066

4.  A comparative study of stress-mediated immunological functions with the adjuvanticity of alum.

Authors:  Yufei Wang; Durdana Rahman; Thomas Lehner
Journal:  J Biol Chem       Date:  2012-04-03       Impact factor: 5.157

5.  Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice.

Authors:  Songnian Fu; Jiangtao Wang; Chenguang Hao; Haihong Dang; Sheng Jiang
Journal:  Psychopharmacology (Berl)       Date:  2019-03-07       Impact factor: 4.530

Review 6.  Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury.

Authors:  Jason K Karimy; Benjamin C Reeves; Kristopher T Kahle
Journal:  Expert Opin Ther Targets       Date:  2020-04-17       Impact factor: 6.902

7.  HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer.

Authors:  Shuxun Liu; Lin Yi; Ma Ling; Jinxia Jiang; Lijun Song; Juan Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2016-06-27       Impact factor: 11.530

8.  TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.

Authors:  Hongliang Fang; Bing Ang; Xinyun Xu; Xiaohui Huang; Yanfeng Wu; Yanping Sun; Wenying Wang; Nan Li; Xuetao Cao; Tao Wan
Journal:  Cell Mol Immunol       Date:  2013-12-23       Impact factor: 11.530

Review 9.  Innate immunity and its regulation by mast cells.

Authors:  Ashley L St John; Soman N Abraham
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

Review 10.  MicroRNAs in the regulation of TLR and RIG-I pathways.

Authors:  Yingke Li; Xueyin Shi
Journal:  Cell Mol Immunol       Date:  2012-12-24       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.